{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:01:30Z","timestamp":1792216890551,"version":"4.4.0"},"reference-count":53,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Studies have suggested a rise in opioid- and stimulant-involved overdoses in recent years in North America. This risk may be acute for individuals who have had contact with the criminal justice system, who are particularly vulnerable to overdose risk.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To examine the association of opioid and\/or stimulant use disorder diagnoses with overdose (fatal and nonfatal) among people with histories of incarceration.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n In this cohort study, population-based health and corrections data were retrieved from the British Columbia Provincial Overdose Cohort, which contains a 20% random sample of residents of British Columbia. The analysis included all people in the 20% random sample who had a history of incarceration between January 1, 2010, and December 31, 2014. Outcomes were derived from 5-years of follow-up data (January 1, 2015, to December 31, 2019). Statistical analysis took place from January 2022 to June 2022.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Substance use disorder diagnosis type (ie, opioid use disorder, stimulant use disorder, both, or neither), sociodemographic, health, and incarceration characteristics.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Hazard ratios (HRs) are reported from an Andersen-Gill model for recurrent nonfatal overdose events and from a Fine and Gray competing risk model for fatal overdose events.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The study identified 6816 people (5980 male [87.7%]; 2820 aged &amp;lt;30 years [41.4%]) with histories of incarceration. Of these, 293 (4.3%) had opioid use disorder only, 395 (6.8%) had stimulant use disorder only, and 281 (4.1%) had both diagnoses. During follow-up, 1655 people experienced 4026 overdoses including 3781 (93.9%) nonfatal overdoses, and 245 (6.1%) fatal overdoses. In adjusted analyses, the hazard of both fatal (HR, 2.39; 95% CI, 1.48-3.86) and nonfatal (HR, 2.45; 95% CI, 1.94-3.11) overdose was highest in the group with both opioid and stimulant use disorder diagnoses.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This cohort study of people with a history of incarceration found an elevated hazard of fatal and nonfatal overdose among people with both opioid and stimulant use disorder diagnoses. This study suggests an urgent need to address the service needs of individuals who have had contact with the criminal justice system and who co-use opioids and stimulants.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.43653","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T11:33:57Z","timestamp":1669203237000},"page":"e2243653","source":"Crossref","is-referenced-by-count":24,"title":["Association of Opioid and Stimulant Use Disorder Diagnoses With Fatal and Nonfatal Overdose Among People With a History of Incarceration"],"prefix":"10.1001","volume":"5","author":[{"given":"Heather","family":"Palis","sequence":"first","affiliation":[{"name":"BC Centre for Disease Control, Vancouver, British Columbia, Canada"},{"name":"Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"Gan","sequence":"additional","affiliation":[{"name":"BC Centre for Disease Control, Vancouver, British Columbia, Canada"},{"name":"Department of Public Health Sciences, University of Connecticut School of Medicine, Farmington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Xavier","sequence":"additional","affiliation":[{"name":"BC Centre for Disease Control, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshni","family":"Desai","sequence":"additional","affiliation":[{"name":"BC Centre for Disease Control, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marnie","family":"Scow","sequence":"additional","affiliation":[{"name":"BC Centre for Disease Control, Vancouver, British Columbia, Canada"},{"name":"School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kali-olt","family":"Sedgemore","sequence":"additional","affiliation":[{"name":"BC Centre for Disease Control, Vancouver, British Columbia, Canada"},{"name":"Coalition of Peers Dismantling the Drug War, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh","family":"Greiner","sequence":"additional","affiliation":[{"name":"BC Corrections, Victoria, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonia","family":"Nicholls","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"BC Mental Health and Substance Use Services, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Slaunwhite","sequence":"additional","affiliation":[{"name":"BC Centre for Disease Control, Vancouver, British Columbia, Canada"},{"name":"School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,11,23]]},"reference":[{"key":"zoi221229r3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.drugalcdep.2018.08.029","article-title":"Twin epidemics: the surging rise of methamphetamine use in chronic opioid users.","volume":"193","author":"Ellis","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"17","key":"zoi221229r4","doi-asserted-by":"publisher","DOI":"10.1186\/s13011-021-00350-5","article-title":"\u2018Resurgent\u2019, \u2018twin\u2019 or \u2018silent\u2019 epidemic: a select data overview and observations on increasing psycho-stimulant use and harms in North America.","volume":"16","author":"Fischer","year":"2021","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"7","key":"zoi221229r5","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1176\/appi.ps.202000927","article-title":"Prevalence of mental health needs, substance use and co-occurring disorders among people admitted to prison.","volume":"73","author":"Butler","year":"2021","journal-title":"Psychiatr Serv"},{"issue":"3","key":"zoi221229r6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.0558","article-title":"Health, polysubstance use, and criminal justice involvement among adults with varying levels of opioid use.","volume":"1","author":"Winkelman","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"2","key":"zoi221229r7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/ADM.0b013e318239c30a","article-title":"Psychostimulant-related deaths among former inmates.","volume":"6","author":"Calcaterra","year":"2012","journal-title":"J Addict Med"},{"issue":"13","key":"zoi221229r8","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1080\/10826084.2020.1795683","article-title":"Polysubstance use patterns among justice-involved individuals who use opioids.","volume":"55","author":"Bunting","year":"2020","journal-title":"Subst Use Misuse"},{"issue":"8","key":"zoi221229r11","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1046\/j.1360-0443.2003.00474.x","article-title":"The ratio of non-fatal to fatal heroin overdose.","volume":"98","author":"Darke","year":"2003","journal-title":"Addiction"},{"issue":"1","key":"zoi221229r13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210129","article-title":"Development and characteristics of the provincial overdose cohort in British Columbia, Canada.","volume":"14","author":"MacDougall","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"zoi221229r14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/add.v117.1","article-title":"Prevalence of co-occurring mental illness and substance use disorder and association with overdose: a linked data cohort study among residents of British Columbia, Canada.","volume":"117","author":"Keen","year":"2022","journal-title":"Addiction"},{"issue":"1","key":"zoi221229r15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data.","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"issue":"4","key":"zoi221229r16","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1214\/aos\/1176345976","article-title":"Cox\u2019s regression model for counting processes: a large sample study.","volume":"10","author":"Andersen","year":"1982","journal-title":"Ann Stat"},{"issue":"4","key":"zoi221229r19","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/dar.v41.4","article-title":"Overdose deaths and the COVID-19 pandemic in British Columbia, Canada.","volume":"41","author":"Palis","year":"2022","journal-title":"Drug Alcohol Rev"},{"key":"zoi221229r20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugpo.2017.05.044","article-title":"The impact of cocaine use in patients enrolled in opioid agonist therapy in Ontario, Canada.","volume":"48","author":"Franklyn","year":"2017","journal-title":"Int J Drug Policy"},{"issue":"9","key":"zoi221229r21","doi-asserted-by":"publisher","first-page":"e247","DOI":"10.1503\/cmaj.170958","article-title":"Management of opioid use disorders: a national clinical practice guideline.","volume":"190","author":"Bruneau","year":"2018","journal-title":"CMAJ"},{"issue":"1","key":"zoi221229r22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/add.v114.1","article-title":"One size does not fit all-evolution of opioid agonist treatments in a naturalistic setting over 23 years.","volume":"114","author":"Nordt","year":"2019","journal-title":"Addiction"},{"key":"zoi221229r23","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s00213-020-05563-3","article-title":"Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis.","volume":"237","author":"Tardelli","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"issue":"10034","key":"zoi221229r25","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1016\/S0140-6736(16)00205-1","article-title":"Sustained-release dexamfetamine in the treatment of chronic cocaine-dependent patients on heroin-assisted treatment: a randomised, double-blind, placebo-controlled trial.","volume":"387","author":"Nuijten","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"zoi221229r26","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/add.v115.5","article-title":"Clinical effects beyond cocaine use of sustained-release dexamphetamine for the treatment of cocaine dependent patients with comorbid opioid dependence: secondary analysis of a double-blind, placebo-controlled randomized trial.","volume":"115","author":"Blanken","year":"2020","journal-title":"Addiction"},{"issue":"68","key":"zoi221229r27","doi-asserted-by":"publisher","DOI":"10.1186\/s13011-021-00399-2","article-title":"Exploring the effectiveness of dextroamphetamine for the treatment of stimulant use disorder: a qualitative study with injectable opioid agonist treatment patients.","volume":"16","author":"Palis","year":"2021","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"57","key":"zoi221229r28","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-021-00500-9","article-title":"Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report.","volume":"18","author":"Palis","year":"2021","journal-title":"Harm Reduct J"},{"issue":"10","key":"zoi221229r29","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/jamapsychiatry.2021.1969","article-title":"Contingency management for patients receiving medication for opioid use disorder: a systematic review and meta-analysis.","volume":"78","author":"Bol\u00edvar","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"zoi221229r30","doi-asserted-by":"publisher","first-page":"04009","DOI":"10.7189\/jogh.11.04009","article-title":"The prevalence of adult attention-deficit hyperactivity disorder: a global systematic review and meta-analysis.","volume":"11","author":"Song","year":"2021","journal-title":"J Glob Health"},{"issue":"2","key":"zoi221229r31","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1017\/S0033291714000762","article-title":"A meta-analysis of the prevalence of attention deficit hyperactivity disorder in incarcerated populations.","volume":"45","author":"Young","year":"2015","journal-title":"Psychol Med"},{"issue":"1","key":"zoi221229r32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000487767","article-title":"ICASA consensus group. International consensus statement on screening, diagnosis and treatment of substance use disorder patients with comorbid attention deficit\/hyperactivity disorder.","volume":"24","author":"Crunelle","year":"2018","journal-title":"Eur Addict Res"},{"issue":"1","key":"zoi221229r33","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.drugalcdep.2006.07.004","article-title":"Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo.","volume":"87","author":"Levin","year":"2007","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"zoi221229r34","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.0707e18","article-title":"Diagnosing ADHD in adults with substance use disorder: DSM-IV criteria and differential diagnosis.","volume":"68","author":"Levin","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"23","key":"zoi221229r35","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.2174\/1381612821666150619093254","article-title":"Methylphenidate in adults with attention deficit hyperactivity disorder and substance use disorders.","volume":"21","author":"Simon","year":"2015","journal-title":"Curr Pharm Des"},{"issue":"3","key":"zoi221229r36","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/add.2014.109.issue-3","article-title":"Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial.","volume":"109","author":"Konstenius","year":"2014","journal-title":"Addiction"},{"issue":"1","key":"zoi221229r37","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.9778\/cmajo.20190106","article-title":"Supporting women leaving prison through peer health mentoring: a participatory health research study.","volume":"8","author":"McLeod","year":"2020","journal-title":"CMAJ Open"},{"key":"zoi221229r38","doi-asserted-by":"publisher","DOI":"10.1177\/1178221820976988","article-title":"Targeting the barriers in the substance use disorder continuum of care with peer recovery support.","volume":"15","author":"Stanojlovic","year":"2021","journal-title":"Subst Abuse"},{"issue":"10","key":"zoi221229r39","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.30795","article-title":"Assessment of stimulant use and cardiovascular event risks among older adults.","volume":"4","author":"Tadrous","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zoi221229r40","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.amjmed.2018.11.038","article-title":"National rate of tobacco and substance use disorders among hospitalized heart failure patients.","volume":"132","author":"Snow","year":"2019","journal-title":"Am J Med"},{"issue":"13","key":"zoi221229r42","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1007\/s11606-022-07692-1","article-title":"A chronic condition disguised as an acute event: the case for re-thinking stimulant overdose death.","volume":"37","author":"Riley","year":"2022","journal-title":"J Gen Intern Med"},{"issue":"9","key":"zoi221229r43","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.jchf.2019.06.010","article-title":"Carvedilol among patients with heart failure with a cocaine-use disorder.","volume":"7","author":"Banerji","year":"2019","journal-title":"JACC Heart Fail"},{"key":"zoi221229r44","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/1985379","article-title":"Beta blocker therapy in heart failure patients with active cocaine use: a systematic review.","volume":"2020","author":"Mann","year":"2020","journal-title":"Cardiol Res Pract"},{"issue":"4","key":"zoi221229r45","doi-asserted-by":"publisher","first-page":"E127","DOI":"10.1503\/cmaj.211347","article-title":"Avoidance of \u00df-blockers in patients who use stimulants is not supported by good evidence.","volume":"194","author":"Wilson","year":"2022","journal-title":"CMAJ"},{"issue":"2","key":"zoi221229r46","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10140-011-1013-0","article-title":"Reversible delayed posthypoxic leukoencephalopathy after drug overdose: MRI findings in a collection of patients.","volume":"19","author":"Betts","year":"2012","journal-title":"Emerg Radiol"},{"key":"zoi221229r47","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108830","article-title":"Trends and outcomes of serious complications associated with non-fatal opioid overdoses in Ontario, Canada.","volume":"225","author":"Kitchen","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"zoi221229r48","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108838","article-title":"Neurocognitive impairments and brain abnormalities resulting from opioid-related overdoses: a systematic review.","volume":"226","author":"Winstanley","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"zoi221229r49","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108435","article-title":"Predictors of enrollment in opioid agonist therapy after opioid overdose or diagnosis with opioid use disorder: a cohort study.","volume":"219","author":"Macmadu","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"46","key":"zoi221229r51","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-022-00630-8","article-title":"Identifying behaviours for survival and wellness among people who use methamphetamine with opioids in British Columbia: a qualitative study.","volume":"19","author":"Corser","year":"2022","journal-title":"Harm Reduct J"},{"issue":"9","key":"zoi221229r52","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1111\/add.2010.105.issue-9","article-title":"Meta-analysis of drug-related deaths soon after release from prison.","volume":"105","author":"Merrall","year":"2010","journal-title":"Addiction"},{"issue":"9","key":"zoi221229r53","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1111\/add.v115.9","article-title":"Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services.","volume":"115","author":"Krawczyk","year":"2020","journal-title":"Addiction"},{"key":"zoi221229r1","unstructured":"Government of Canada. Opioid and stimulant related harms in Canada. Accessed October 21, 2022. https:\/\/health-infobase.canada.ca\/substance-related-harms\/opioids-stimulants\/"},{"key":"zoi221229r2","unstructured":"BC Coroners Service. Illicit drug toxicity deaths in BC January 1, 2011-December 31, 2021. Accessed January 5th, 2022. https:\/\/www2.gov.bc.ca\/assets\/gov\/birth-adoption-death-marriage-and-divorce\/deaths\/coroners-service\/statistical\/illicit-drug.pdf"},{"key":"zoi221229r9","doi-asserted-by":"crossref","unstructured":"Gan? WQ, Kinner? SA, Nicholls? TL, . Risk of overdose-related death for people with a history of incarceration.? Addiction. Published online November 27, 2020. doi:10.1111\/add.1529333047844","DOI":"10.23889\/ijpds.v5i5.1470"},{"key":"zoi221229r10","doi-asserted-by":"crossref","unstructured":"Keen? C, Kinner? SA, Young? JT, . Periods of altered risk for non-fatal drug overdose: a self-controlled case series.? The Lancet. 2021;6(4):e249-e259. doi:10.1016\/S2468-2667(21)00007-4","DOI":"10.1016\/S2468-2667(21)00007-4"},{"key":"zoi221229r12","unstructured":"British Columbia Ministry of Health, British Columbia Centre on Substance Use. Risk mitigation in the context of dual public health emergencies. Accessed October 21, 2022. https:\/\/www.bccsu.ca\/wp-content\/uploads\/2020\/04\/Risk-Mitigation-in-the-Context-of-Dual-Public-Health-Emergencies-v1.5.pdf"},{"key":"zoi221229r17","unstructured":"Gray? B. Subdistribution analysis of competing risks. R Project. Accessed October 21, 2022. https:\/\/cran.r-project.org\/web\/packages\/cmprsk\/cmprsk.pdf"},{"key":"zoi221229r18","unstructured":"Therneau? T, Crowson? C, Atkinson? E. Using time dependent covariates and time dependent coefficients in the Cox model. Accessed October 21, 2022. https:\/\/cran.r-project.org\/web\/packages\/survival\/vignettes\/timedep.pdf"},{"key":"zoi221229r24","unstructured":"Treatment of stimulant use disorders: current practices and promising perspectives. United Nations Office on Drugs and Crime. Accessed October 21, 2022. https:\/\/www.unodc.org\/documents\/drug-prevention-and-treatment\/Treatment_of_PSUD_for_website_24.05.19.pdf"},{"key":"zoi221229r41","doi-asserted-by":"crossref","unstructured":"Gan? WQ, Buxton? JA, Palis? H, . Drug overdose and the risk of cardiovascular diseases: a nested case-control study. Clin Res Cardiol. Published online 2021. doi:10.1007\/s00392-021-01945-534654963","DOI":"10.1007\/s00392-021-01945-5"},{"key":"zoi221229r50","unstructured":"BC coroners service death review panel: a review of illicit drug toxicity deaths. BC Coroners Service. Accessed October 21, 2022. https:\/\/www2.gov.bc.ca\/assets\/gov\/birth-adoption-death-marriage-and-divorce\/deaths\/coroners-service\/death-review-panel\/review_of_illicit_drug_toxicity_deaths_2022.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2798900\/palis_2022_oi_221229_1668537405.00044.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T11:34:07Z","timestamp":1669203247000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2798900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,23]]},"references-count":53,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.43653","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,23]]}}}